JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12
BenzingaMay 3 15:17 ET
Vir Biotechnology Analyst Ratings
BenzingaMay 3 15:14 ET
Hold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial Uncertainty
TipRanksMay 3 07:12 ET
Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)
TipRanksMay 3 06:42 ET
Buy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment Milestones
TipRanksMay 3 06:27 ET
Vir Biotechnology Analyst Ratings
BenzingaMar 15 09:25 ET
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
TipRanksMar 15 06:20 ET
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
TipRanksMar 11 00:46 ET
Optimistic Outlook for Vir Biotechnology's Clinical Programs and Financial Position Reinforces Buy Rating
TipRanksFeb 25 23:29 ET
Vir Biotechnology Analyst Ratings
BenzingaFeb 23 12:32 ET
Maintaining Hold on Vir Biotechnology Amid Revenue Decline and Strategic Pivot
TipRanksFeb 23 07:16 ET
Barclays Issues a Buy Rating on Vir Biotechnology (VIR)
TipRanksFeb 23 03:05 ET
Vir Biotechnology Analyst Ratings
BenzingaFeb 14 06:39 ET
JP Morgan Cuts Vir to Neutral, Cites Hepatitis Drug Franchise Concerns
Seeking AlphaJan 29 14:19 ET
JP Morgan Downgrades Vir Biotechnology to Neutral, Lowers Price Target to $9
BenzingaJan 29 06:06 ET
Vir Biotechnology Analyst Ratings
BenzingaJan 29 06:04 ET
Vir Biotechnology Analyst Ratings
BenzingaJan 23 06:40 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Airsculpt Technologies, Inc. (AIRS), Vir Biotechnology (VIR) and Gilead Sciences (GILD)
TipRanksNov 20, 2023 01:40 ET
Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Vir Biotechnology (VIR)
TipRanksNov 14, 2023 12:20 ET
Vir Biotechnology's Promising Phase 2 Trials Propel Buy Rating: A Focus on HDV and HBV Treatment Advancements
TipRanksNov 14, 2023 01:58 ET
No Data
No Data